High Id1 expression is associated with poor prognosis in 237 patients with acute myeloid leukemia

Blood

Volumn 114, Issue 14, 2009, Pages 2993-3000

  Tang, Ruoping ^a,b   Hirsch, Pierre ^a,b,c   Fava, Fanny ^a,b   Lapusan, Simona ^a   Marzac, Christophe ^c   Teyssandier, Irène ^c   Pardo, Julia ^b   Marie, Jean Pierre ^a,b   Legrand, Ollivier ^a,b  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c HÔPITAL SAINT ANTOINE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD135 ANTIGEN; INHIBITOR OF DIFFERENTIATION 1; MOLECULAR MARKER; PROTEIN TYROSINE KINASE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; CONTROLLED STUDY; CYTOGENETICS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE FREE SURVIVAL; ENZYME ACTIVATION; FEMALE; GENE DUPLICATION; GROUPS BY AGE; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REMISSION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; FMS-LIKE TYROSINE KINASE 3; HUMANS; INHIBITOR OF DIFFERENTIATION PROTEIN 1; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MUTATION; NEOPLASM PROTEINS; NUCLEAR PROTEINS; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK FACTORS; RNA, MESSENGER; SURVIVAL RATE; TANDEM REPEAT SEQUENCES; YOUNG ADULT;

EID: 70449495051     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-05-223115     Document Type: Article

References (55)

1. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 trial. Blood. 1998;92(7):2322-2333. (Pubitemid 28452973)
2. Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood. 2000;96(13):4075-4083.
3. Byrd JC, Mrózek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002;100(13):4325-4336. (Pubitemid 35429670)
4. Mrózek K, Heerema NA, Bloomfield CD. Cytogenetics in acute leukemia. Blood Rev. 2004;18(2): 115-136.
5. Schnittger S, Schoch C, Dugas M, et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood. 2002; 100(1):59-66. (Pubitemid 35177429)
6. Fröhling S, Schlenk RF, Breitruck J, et al. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood. 2002; 100(13):4372-4380. (Pubitemid 35434129)
7. Thiede C, Steudel C, Mohr B, et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood. 2002;99(12):4326- 4335. (Pubitemid 34627197)
8. Preudhomme C, Sagot C, Boissel N, et al. Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA). Blood. 2002;100(8):2717-2723.
9. Fröhling S, Schlenk RF, Stolze I, et al. CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations. J Clin Oncol. 2004;22(4):624-633. (Pubitemid 41095065)
10. Langer C, Radmacher MD, Ruppert AS, et al. High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study. Blood. 2008; 111(11):5371-5379.
11. Schnittger S, Schoch C, Kern W, et al. Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood. 2005;106(12): 3733-3739. (Pubitemid 41739006)
12. Döhner K, Schlenk RF, Habdank M, et al. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood. 2005;106(12):3740-3746. (Pubitemid 41739007)
13. Schlenk RF, Döhner K, Krauter J, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med. 2008; 358(18):1909-1918. (Pubitemid 351620111)
14. Lennartsson J, Jelacic T, Linnekin D, Shivakrupa R. Normal and oncogenic forms of the receptor tyrosine kinase kit. Stem Cells. 2005;23(1):16-43. (Pubitemid 40105289)
15. Stirewalt DL, Radich JP. The role of FLT3 in haematopoietic malignancies. Nat Rev Cancer. 2003;3(9):650-665.
16. Braun BS, Shannon K. Targeting Ras in myeloid leukemias. Clin Cancer Res. 2008;14(8):2249-2252.
17. Nerlov C. C/EBPalpha mutations in acute myeloid leukaemias. Nat Rev Cancer. 2004;4(5):394-400. (Pubitemid 38579485)
18. Ernst P, Wang J, Korsmeyer SJ. The role of MLL in hematopoiesis and leukemia. Curr Opin Hematol. 2002;9(4):282-287.
19. Grisendi S, Mecucci C, Falini B, Pandolfi PP. Nucleophosmin and cancer. Nat Rev Cancer. 2006; 6(7):493-505.
20. Verhaak RG, Goudswaard CS, van Putten W, et al. Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. Blood. 2005;106(12): 3747-3754.
21. Norton JD. ID helix-loop-helix proteins in cell growth, differentiation and tumorigenesis. J Cell Sci. 2000;113(22):3897-3905. (Pubitemid 32194515)
22. Benezra R, Davis RL, Lockshon D, Turner DL, Weintraub H. The protein Id: a negative regulator of helix-loop-helix DNA binding proteins. Cell. 1990;61(1):49-59. (Pubitemid 20134378)
23. Wilson RB, Kiledjian M, Shen CP, et al. Repression of immunoglobulin enhancers by the helix-loop- helix protein Id: implications for B-lymphoid-cell development. Mol Cell Biol. 1991;11(12): 6185-6191. (Pubitemid 21895391)
24. Iavarone A, Garg P, Lasorella A, Hsu J, Israel MA. The helix-loop-helix protein Id-2 enhances cell proliferation and binds to the retinoblastoma protein. Genes Dev. 1994;8(11):1270-1284. (Pubitemid 24181319)
25. Lasorella A, Iavarone A, Israel MA. Id2 specifi- cally alters regulation of the cell cycle by tumor suppressor proteins. Mol Cell Biol. 1996;16(6): 2570-2578. (Pubitemid 26161260)
26. Alani RM, Young AZ, Shifflett CB. Id1 regulation of cellular senescence through transcriptional repression of p16/Ink4a. Proc Natl Acad Sci U S A. 2001;98(14):7812-7816.
27. Ohtani N, Zebedee Z, Huot TJ, et al. Opposing effects of Ets and Id proteins on p16INK4a expression during cellular senescence. Nature. 2001;409(6823):1067-1070. (Pubitemid 32204062)
28. Caldon CE, Swarbrick A, Lee CS, Sutherland RL, Musgrove EA. The helix-loop-helix protein Id1 requires cyclin D1 to promote the proliferation of mammary epithelial cell acini. Cancer Res. 2008; 68(8):3026-3036.
29. Sikder HA, Devlin MK, Dunlap S, Ryu B, Alani RM. Id proteins in cell growth and tumorigenesis. Cancer Cell. 2003;3(6):525-530.
30. Lin CQ, Singh J, Murata K, et al. A role for Id-1 in the aggressive phenotype and steroid hormone response of human breast cancer cells. Cancer Res. 2000;60(5):1332-1340. (Pubitemid 30152003)
31. Ouyang XS, Wang X, Lee DT, Tsao SW, Wong YC. Over expression of ID-1 in prostate cancer. J Urol. 2002;167(6):2598-2602.
32. Maruyama H, Kleeff J, Wildi S, et al. Id-1 and Id-2 are overexpressed in pancreatic cancer and in dysplastic lesions in chronic pancreatitis. Am J Pathol. 1999;155(3):815-822. (Pubitemid 29426827)
33. Schindl M, Oberhuber G, Obermair A, Schoppmann SF, Karner B, Birner P. Overexpression of Id-1 protein is a marker for unfavorable prognosis in early-stage cervical cancer. Cancer Res. 2001;61(15):5703-5706. (Pubitemid 32769080)
34. Schindl M, Schoppmann SF, Ströbel T, et al. Level of Id-1 protein expression correlates with poor differentiation, enhanced malignant potential, and more aggressive clinical behavior of epithelial ovarian tumors. Clin Cancer Res. 2003; 9(2):779-785. (Pubitemid 36182615)
35. Fong S, Itahana Y, Sumida T, et al. Id-1 as a molecular target in therapy for breast cancer cell invasion and metastasis. Proc Natl Acad Sci U S A. 2003;100(23):13543-13548. (Pubitemid 37444778)
36. Jang KS, Han HX, Paik SS, Brown PH, Kong G. Id-1 overexpression in invasive ductal carcinoma cells is significantly associated with intratumoral microvessel density in ER-negative/node-positive breast cancer. Cancer Lett. 2006;244(2):203-210. (Pubitemid 44485879)
37. Schoppmann SF, Schindl M, Bayer G, et al. Overexpression of Id-1 is associated with poor clinical outcome in node negative breast cancer. Int J Cancer. 2003;104(6):677-682. (Pubitemid 36418503)
38. Ling MT, Wang X, Lee DT, Tam PC, Tsao SW, Wong YC. Id-1 expression induces androgen-independent prostate cancer cell growth through activation of epidermal growth factor receptor (EGF-R). Carcinogenesis. 2004;25(4):517-525. (Pubitemid 38499942)
39. Ling MT, Wang X, Ouyang XS, Xu K, Tsao SW, Wong YC. Id-1 expression promotes cell survival through activation of NF-kappaB signalling pathway in prostate cancer cells. Oncogene. 2003; 22(29):4498-4508.
40. Lin CQ, Singh J, Murata K, et al. A role for Id-1 in the aggressive phenotype and steroid hormone response of human breast cancer cells. Cancer Res. 2000;60(5):1332-1340. (Pubitemid 30152003)
41. Ouyang XS, Wang X, Ling MT, Wong HL, Tsao SW, Wong YC. Id-1 stimulates serum independent prostate cancer cell proliferation through inactivation of p16 (INK4a)/pRB pathway. Carcinogenesis. 2002;23(5):721-725. (Pubitemid 34567509)
42. Cheung HW, Ling MT, Tsao SW, Wong YC, Wang X. Id-1-induced Raf/MEK pathway activation is essential for its protective role against taxol-induced apoptosis in nasopharyngeal carcinoma cells. Carcinogenesis. 2004;25(6):881-887. (Pubitemid 38898634)
43. Zhang X, Ling MT, Wong YC, Wang X. Evidence of a novel antiapoptotic factor: role of inhibitor of differentiation or DNA binding (Id-1) in anticancer drug-induced apoptosis. Cancer Sci. 2007;98(3): 308-314. (Pubitemid 46195599)
44. Gautschi O, Tepper CG, Purnell PR, et al. Regulation of Id1 expression by SRC: implications for targeting of the bone morphogenetic protein pathway in cancer. Cancer Res. 2008;68(7):2250-2258.
45. Tam WF, Gu TL, Chen J, et al. Id1 is a common downstream target of oncogenic tyrosine kinases in leukemic cells. Blood. 2008;112(5):1981-1992.
46. Suh HC, Leeanansaksiri W, Ji M, et al. Id1 immortalizes hematopoietic progenitors in vitro and promotes a myeloproliferative disease in vivo. Oncogene. 2008;27:5612-5623.
47. Swarbrick A, Roy E, Allen T, Bishop JM. Id1 cooperates with oncogenic Ras to induce metastatic mammary carcinoma by subversion of the cellular senescence response. Proc Natl Acad Sci U S A. 2008;105(14):5402-5407. (Pubitemid 351753875)
48. Willemze R, Suciu S, Mandelli F, et al High dose (HD-AraC) vs standard dose cytosine arabinoside (SDAraC) during induction and value of IL-2 during maintenance in acute myelogenous leukemia (AML): impact of AraC dose on complete remission rate and toxicity (results on the first 1700 randomized patients of the AML-12 trial of EORTC and GIMEMA Leukemia Groups). Blood. 2008;112:Abstract 134.
49. Suciu S, Mandelli F, de Witte T, et al. Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial. Blood. 2003;102(4):1232-1240.
50. Amadori S, Suciu S, Jehn U, et al. Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 study. Blood. 2005;106(1):27-34. (Pubitemid 40967170)
51. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanatephenol- chloroform extraction. Anal Biochem. 1987;162(1):156-159.
52. Marzac C, Teyssandier I, Calendini O, et al. Flt3 internal tandem duplication and P-glycoprotein functionality in 171 patients with acute myeloid leukemia. Clin Cancer Res. 2006;12(23):7018-7024. (Pubitemid 44974498)
53. Zhang X, Ling MT, Wang X, Wong YC. Inactivation of Id-1 in prostate cancer cells: a potential therapeutic target in inducing chemosensitization to taxol through activation of JNK pathway. Int J Cancer. 2006;118(8):2072-2081.
54. Goodman SN, Berlin JA. The use of predicted confidence intervals when planning experiments ansd the misuse of power when interpreting results. Ann Intern Med. 1994;121(3):200-206.
55. Gale RE, Green C, Allen C, et al. The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood. 2008;111(5): 2776-2784.